866-997-4948(US-Canada Toll Free)

Neuroendocrine Tumors Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 87 Pages


Neuroendocrine Tumors Pipeline Review, H2 2012

Global Markets Directs, 'Neuroendocrine Tumors Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors. Neuroendocrine Tumors Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Neuroendocrine Tumors.
  • A review of the Neuroendocrine Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Neuroendocrine Tumors pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Neuroendocrine Tumors Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Neuroendocrine Tumors 9
Neuroendocrine Tumors Therapeutics under Development by Companies 11
Neuroendocrine Tumors Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Neuroendocrine Tumors Therapeutics Products under Development by Companies 18
Neuroendocrine Tumors Therapeutics Products under Investigation by Universities/Institutes 19
Companies Involved in Neuroendocrine Tumors Therapeutics Development 20
F. Hoffmann-La Roche Ltd. 20
Eli Lilly and Company 21
Novartis AG 22
Molecular Insight Pharmaceuticals, Inc. 23
Gradalis Inc. 24
Neuroendocrine Tumors Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
everolimus - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
iobenguane I 131 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
yttrium Radiotherapy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sorafenib + RAD001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RAD001 + Temozolomide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Octreotide Acetate + Bevacizumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pazopanib hydrochloride - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lanreotide acetate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Platinol + Gemzar + Interferon-Alpha + Hyperthermia Therapy - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
lithium carbonate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PTK-787 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Avastin + 5-Fluorouracil + Streptozotocin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
pazopanib hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Octreotide + Bevacizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Onalta + Retinoic Acid - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
sunitinib malate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
sunitinib malate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
everolimus - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
octreotide acetate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IMC-A12 + Octreotide - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pazopanib hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Irinotecan + Cisplatin + Octreotide Lar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 66
Temozolomide + Vorinostat - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
pazopanib hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
X-82 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
pasireotide + everolimus - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Temozolomide + Pazopanib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Capecitabine + Temozolomide + Bevacizumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Pbi-shRNA PDX-1 LP - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Neuroendocrine Tumors Therapeutics Drug Profile Updates 77
Neuroendocrine Tumors Therapeutics Discontinued Products 83
Neuroendocrine Tumors Therapeutics - Dormant Products 84
Neuroendocrine Tumors Product Development Milestones 85
Featured News & Press Releases 85
Oct 07, 2008: Neotropix Receives Orphan Drug Designation For NTX-010 From FDA. 85
May 17, 2006: Neotropix Receives FDA Approval To Begin Clinical Trials With First Investigational Cancer Drug For NTX-010. 85

Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Table


Number of Products Under Development for Neuroendocrine Tumors, H2 2012 9
Products under Development for Neuroendocrine Tumors Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
F. Hoffmann-La Roche Ltd., H2 2012 20
Eli Lilly and Company, H2 2012 21
Novartis AG, H2 2012 22
Molecular Insight Pharmaceuticals, Inc., H2 2012 23
Gradalis Inc., H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Neuroendocrine Tumors Therapeutics Drug Profile Updates 77
Neuroendocrine Tumors Therapeutics Discontinued Products 83
Neuroendocrine Tumors Therapeutics Dormant Products 84

List of Chart


Number of Products under Development for Neuroendocrine Tumors, H2 2012 9
Products under Development for Neuroendocrine Tumors Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *